Dexcel gets right to sell copycat Prilosec

The fight is over. Over-the-counter drug distributor Perrigo said its partner Dexcel Pharma Technologies has settled patent litigation with AstraZeneca over the heartburn med Prilosec OTC. The settlement deal will allow Dexcel to sell a store-brand version of the drug as soon as it gets FDA's approval.

The patent fight has been going on since May 2006, when AZ sued to block Dexcel's new drug application. Now, AZ has waived its patent claims on Dexcel's product. Perrigo, which will be the exclusive distributor for the drug, expecting sales of $150 million to $200 million. Overall, Prilosec OTC sells at the rate of $750 million annually.

- see this release from Perrigo (.pdf)
- read the report from the Houston Chronicle

Related Articles:
Canada questions safety of Nexium, Prilosec. Report
FDA to review Nexium, Prilosec. Report

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.